The additional funding of $50M originally from LPC and now with Cantor (better I believe) may or may not be drawn down in full. It may also well be the case that the 3 currently planned trials given the incentives in Australia, potential grants and the support of the universal health care systems of Australian, Europe and perhaps Canada, is sufficient.
Anavex also have a very interesting pipeline e.g. A3-71 with ODD granted by the FDA for FTD, compounds for cancer indications etc., which the company has not had the capacity to advance. I think it very likely that we could see activity on those and funding needs as the 3 trials are well under way.
Depending on how far Anavex intend to go it alone on positive readouts in AD, PD and Rett, perhaps at that point and at a higher share price, they will draw on the funding facility to push commercialisation along and reduce any share of revenue going to partners.
Anyway, I believe Anavex have chosen a far more controlled and independent way of handling shareholders interest through the LPC/Cantor funding that being in the hands of Wall St. and secondary offerings.
I remain intrigued to learn more July 25th and from an exciting time with trials ongoing.
Market Data 
Markets 
AI
